The FDA expanded the approved indications for dapagliflozin-containing agents (Farxiga, Xigduo) to include patients with moderate renal impairment, AstraZeneca announced.
Insulin glargine and lixisenatide injection (Soliqua 100/33) also won approval as adjunct therapy to oral antidiabetic medications for adults with uncontrolled type 2 diabetes, Sanofi announced.
Following the death of a 13-year old boy with type 1 diabetes, the herbalist “treating” him while advising his parents to withhold insulin was sentenced to 4 months in jail this week. (NBC News)
The Endocrine Society hit back against new restrictions on the Title X Family Planning Program. “We urge the administration to eliminate these new eligibility criteria to ensure that all centers qualified to provide these services have equal opportunity to receive Title X grant funding,” the society said in a statement.
Laser treatments to treat vaginal atrophy come with risks, described in four case reports. (Reuters, Menopause)
Genetic osteoporosis? Finnish researchers identified gene variants responsible for childhood-onset osteoporosis. (ScienceDaily)
Obesity Society president Steven Heymsfield, MD, along with several other society members, were named as members of the 2020 Dietary Guidelines Advisory Committee.
Did the weedkiller glyphosate (Roundup) cause a man’s cancer? A jury in federal court will soon decide. (NBC News)